Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Health Ministry Presents Proposal to Revise Priority Infectious Diseases
March 12, 2025
- Ishiba Hints at Reflecting Wage Hikes in Drug Pricing
March 11, 2025
- Stelara to Get 40.8% Price Cut on PMP Return, Januvia Over 26% in 2025 Revision
March 10, 2025
- Ishiba Flip-Flops on Copay Cap Hike, Drops Planned Raise in August
March 10, 2025
- NARO Miniaturizes Immunodeficient Pigs for Use in Drug R&D
March 10, 2025
- MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
March 7, 2025
- Govt’s Regulatory Reform Panel Discusses Access to Clinical Trial Information
March 7, 2025
- Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval
March 7, 2025
- New LDP Project Team Holds Hearing for Govt’s Startup Measures
March 6, 2025
- CAR-T Therapies Subject to Label Revision over Lymphoid Neoplasm Risk
March 6, 2025
- Safety-Related Label Revision Ordered for Trulicity, CP Inhibitors, and More
March 6, 2025
- MHLW Taking Applications for Subsidies to Support Generic Consolidation, Biosimilars
March 6, 2025
- Japan’s FY2025 Draft Budget Clears Lower House
March 5, 2025
- Three-Party Talks to Be Held on Health Coverage of OTC-Like Drugs: Minister
March 4, 2025
- No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister
March 3, 2025
- Japan Grants Orphan Tags to Atrasentan, Efzimfotase, and Lots More
March 3, 2025
- Japan to Revisit Copay Cap Hike Plan for 2026 and Beyond: Ishiba
March 3, 2025
- Japan Extends Re-Examination Period for Zeposia, Lupkynis
March 3, 2025
- Japan to Launch Pilot Project for Adopting Fair Market Value in Clinical Trial Costs
February 28, 2025
- LDP Lawmakers Urge Generic Industry to Ramp Up Production
February 28, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…